Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Astellas Buys Amevive from BI | Contract Pharma

What are you searching for?

Sign in
Breaking News

Astellas Buys Amevive from BI

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Astellas Pharma U.S. and Biogen Idec have entered an agreement under which Astellas will purchase the worldwide rights to Amevive, a biologic anti-inflammatory compound used in the treatment of moderate-to-severe plaque psoriasis. Astellas will acquire the worldwide rights to Amevive in all indications from BI, which would continue to manufacture Amevive and supply product to Astellas. The parties anticipate closing the transaction as early as mid-April.

“The acquisition of a well-established product such as Amevive strengthens our North American Dermatology franchise and provides Astellas an opportunity to continue offering physicians this effective option for the treatment of moderate-to-severe plaque psoriasis,” said, William Fitzsimmons, Pharm.D., senior vice president, business development at Astellas Pharma.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters